Login to Your Account



Anergis Preps for Pivotal Trial of Allergy Vaccine, Seeks Partner

By Nuala Moran
Staff Writer

Monday, October 21, 2013
LONDON – Anergis SA released new immunological data from the Phase IIb study of its lead product Allert, proving the synthetic allergy vaccine acts in the same way as traditional desensitizing allergy treatments and providing a comfort factor for potential pharma partners as licensing discussions progress.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription